Novel Therapeutic Interventions Early in the Disease Trajectory: Drug Development Beyond the Refractory Setting.
Antineoplastic Combined Chemotherapy Protocols
/ pharmacology
Biomarkers, Tumor
/ genetics
Chemotherapy, Adjuvant
/ methods
Drug Development
/ methods
Drug Resistance, Neoplasm
/ genetics
Humans
Molecular Targeted Therapy
/ methods
Neoadjuvant Therapy
/ methods
Neoplasm Staging
Neoplasms
/ diagnosis
Precision Medicine
/ methods
Progression-Free Survival
Randomized Controlled Trials as Topic
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
15 09 2020
15 09 2020
Historique:
received:
10
12
2019
revised:
18
05
2020
accepted:
17
06
2020
pubmed:
24
6
2020
medline:
15
12
2021
entrez:
24
6
2020
Statut:
ppublish
Résumé
The 2019 Accelerating Anticancer Agent Development Workshop assembled a panel of experts for an in-depth discussion session to present "novel therapeutic interventions early in the disease trajectory." The panel reviewed the limitations of evaluating investigational cancer therapeutics solely in advanced metastatic and relapsed/refractory disease settings, and recommended strategies for drug evaluation earlier in the disease course, including in the first line in combination with standard chemotherapy, and in the maintenance and neoadjuvant disease settings. Advantages of earlier drug evaluation were discussed, including expanding the population of evaluable patients, earlier response assessment via surrogate endpoints, earlier clinical benefit in the disease course, tailoring of therapies based on response, and furthering our understanding of biomarker-driven therapies.
Identifiants
pubmed: 32571790
pii: 1078-0432.CCR-19-4035
doi: 10.1158/1078-0432.CCR-19-4035
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4743-4747Informations de copyright
©2020 American Association for Cancer Research.